Cashu
Gilead Sciences Sees Yeztugo PrEP as Upside to 2026 Revenue Amid Uptake Uncertainty
2 days ago
Stocks
Health Care
gild
Gilead Sciences
NASDAQ: GILD
+3.17 (+2.09%)
154.98
USD
At close at Feb 13, 21:34 UTC
Overview
Loading chart...
Key Stats
Market Cap
192.30B
Dividend Yield
0.00%
P/E Ratio
23.71
EPS
0.37
Revenue
28.75B
Avg. Volume
9.28M
About
What does GILD do?
Gilead Sciences, headquartered in Foster City, California, employs 18,000 people and focuses on developing medicines for HIV, hepatitis, COVID-19, and cancer. Its portfolio includes numerous marketed products and several promising candidates.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.